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Summary
Alzheimer’s disease (AD) is a neurodegenerative disorder
and the most common cause for dementia, which affects
approximately 120 thousand people in Switzerland and 35
million worldwide. Aging is a major risk factor for devel-
oping AD and thus, as our societies are growing older, we
face great challenges to find treatment strategies. The dis-
ease is characterised by loss of memory, deposition of ex-
tracellular amyloid plaques containing Aβ peptides and in-
traneuronal tangles of the tau protein. To date, there is no
effective treatment and the cause of the disease is still de-
bated.
The Schweizerische Alzheimervereinigung states that we
need “continuous manifold research” into all possible
causes of AD to find a cure for this disease. Fitting this pro-
position, a recent publication by Xia et al. (2015) described
a novel mouse model that for the first time reproduces cor-
tical neuron death as observed in human AD cases. At the
same time, this publication questions the major theory of
AD pathogenesis and points towards different treatment
avenues that should be followed to find a cure for AD.
Key words: Alzheimer’s disease; amyloid precursor protein
(APP); nuclear signaling; presenilin; AICD; neurodegener-
ation
Gain-of-toxicity
Although familial Alzheimer’s disease (FAD) represents
less than 1% of all AD cases, it has been instrumental in
shaping the hypotheses on the pathogenesis of this dis-
ease. FAD is caused by mutations in the amyloid precursor
protein (APP) as well as presenilin 1 (PS1) or PS2, cata-
lytic subunits of the γ-secretase complex. A major break-
through was the discovery that Aβ peptides are generated
by sequential proteolytic cleavage of APP, with the final
intramembraneous γ-secretase cleavage releasing the Aβ
peptide (fig. 1). The majority of Aβ peptides are 40 amino
acids long, but γ-secretase also generates Aβ species of
different length, for example Aβ42, which is more prone
to aggregation because the additional hydrophobic amino
acids derive from the transmembrane region of APP [1].
FAD mutations in the presenilins cause a shift in cleavage,
resulting in generation of more Aβ42, thereby shifting the
Ab42/Aβ40 ratio that is a crucial determinant for the de-
position of amyloid. This is exemplified by transgenic mice
expressing solely Aβ40 or Aβ42 in the absence of APP;
mice with high levels of Aβ40 exhibited no plaque de-
position, whereas mice expressing low levels of Aβ42 had
massive amyloid deposits [2]. Crossing these two mouse
lines abolished plaque formation, i.e. Aβ40 was able to pre-
Figure 1
Proteolytic processing of the amyloid precursor protein (APP).
APP is a single-pass transmembrane protein with a large
extracellular domain and the short APP intracellular domain (AICD)
facing the cytoplasm. Sequential proteolytic cleavage by the
secretases occurs via two opposing pathways, both initiated by the
release of the extracellular domain. Non-amyloidogenic cleavage
by α-secretase destroys the Aβ peptide and releases secreted
APPα (sAPPα). This APP fragment contains a growth factor-like
domain (GFLD) and a copper-binding domain (CBD) and displays
neuroprotective and neuroproliferative properties. In the
amyloidogenic pathway, cleavage by β-secretase generates the Aβ
N-terminus and sAPPβ, which lacks the properties of sAPPα. After
release of the extracellular domain, the remaining APP
transmembrane C-terminal fragments (CTFs) can enter the γ-
secretase complex to undergo regulated intramembrane proteolysis
(RIP), which consists of consecutive cleavages denoted by three
arrows. This initially releases AICD from the membrane, which in
the case of the amyloidogenic pathway can signal to the nucleus. In
the same pathway, further cleavages by γ-secretase shape the Aβ
C-terminus that is critical for determining aggregation propensity.
Aβ aggregates into different oligomeric species that can induce
synapse loss and neurofibrillary tangle (NFT) formation. Finally, Aβ
deposits in large extracellular structures known as amyloid plaques
– besides NFTs, a hallmark of Alzheimer’s disease (AD).
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vent the aggregation and deposition of Aβ42, demonstrat-
ing the importance of the Aβ42/Aβ40 ratio [3].
These findings pointed toward a gain-of-toxic-function of
FAD mutations and led to the formulation of the amyloid
cascade hypothesis. The cause of the disease was thought
to be the aggregation of Aβ into amyloid plaques, resulting
in cell death [4]. Subsequently, this hypothesis was refined
to state that the disease is initiated not by plaques, but by
smaller Aβ oligomers directly influencing synaptic func-
tion, which over time changes neuronal homeostasis, lead-
ing to tangle formation, cell death and dementia [5].The
initiating event is still thought to be a gain-of-toxic-func-
tion of the Aβ peptide.
Aβ peptides can be isolated from affected brains, cell cul-
tures expressing FAD mutant APP or synthesised chemic-
ally. With these different preparations, myriad downstream
effects on cellular processes have been described.
However, it remains to be determined what is essentially
the cause of neurodegeneration or if all processes work
in parallel with different impacts [1, 6]. Especially note-
worthy is the connection of Aβ to tau. Besides Aβ de-
position, the second hallmark of AD is the accumulation
of intracellular neurofibrillary tangles (NFTs) composed of
hyperphosphorylated tau protein. Tau phosphorylation and
aggregation seems to occur downstream of Aβ oligomer-
isation [7, 8], with Aβ activating several tau kinases [9, 10].
Deletion of tau in FAD-APP transgenic mice ameliorates
many of the cognitive deficits, axonal transport deficits and
premature mortality, together demonstrating a central role
of tau in neuronal homeostasis [11].
Unresolved issues
Although a great deal of data in favour of the amyloid
cascade has been reported, there are still some contradic-
tions that need to be resolved. Findings from post mortem
studies revealed persons with an abundance of amyloid
plaques, yet showing no mental deterioration until death
[12]. The advent of imaging techniques for amyloid de-
position in brain has resulted in frequent reports of cognit-
ively healthy elderly with brains full of amyloid plaques
[13–15]. The lack of correlation between dementia severity
and plaque load is opposed by the strong correlation of
synapse loss with dementia [16]. The expression of FAD
mutant APP and PS1 in various transgenic mouse models
has reproduced human amyloid plaque deposition and
memory problems, but has not resulted in widespread
neurodegeneration [17]. Even more, mice that solely ex-
press the Aβ42 peptide, without the rest of the APP molec-
ule, develop strong plaque deposition as described above,
but their cognitive performance is intact [18]. Shutting
down transgenic APP expression in inducible mouse mod-
els corrects abnormal hypersynchronous network activity
and restores cognitive performance with no effect on ex-
isting plaque load [19, 20]. Together, these reports show
that amyloid plaques alone are not sufficient to mimic the
neuropathology of AD.
Loss-of-function
The γ-secretase complex has many more substrates in addi-
tion to APP [21]. A result of the intramembraneous cleav-
age of transmembrane proteins by γ-secretase is the release
of the intracellular domain (ICD) from the membrane,
which in several cases has been shown to signal to the
nucleus to regulate transcription. Many FAD mutations in
the presenilin genes have been shown to lower Aβ40 as
well as APP ICD (AICD) and Notch ICD (NICD) produc-
tion, when analysed by means of in vitro assays [22]. With
highly purified γ-secretase complexes, different FAD muta-
tions in the PS protein lead to a complete loss of AICD
production [23]. In the light of this loss-of-function, the
presenilin hypothesis was put forward to explain neuronal
death in AD [22].
Mice lacking the presenilin 1 gene are not viable [24].
Therefore, mice with a conditional forebrain knockout of
PS1 (cPS1) were generated, to study the effects of loss of
presenilin function in the adult brain [25]. PS1 reduction
was accompanied by accumulation of transmembrane C-
terminal fragments of APP (APP-CTFs = γ-secretase sub-
strates) and reduction of Aβ peptides (γ-secretase
products). Crossing of cPS1 mice to PS2 knockout (KO)
mice, to exclude compensatory effects by this homologue,
resulted in viable mice with intact brain morphology until
6 months of age. This was followed by progressive loss
of grey and white matter and thinning of cortical layers,
accompanied by reduced dendrite complexity and spine
density, as well as disruption of synaptic plasticity and
severe memory impairment. Similar findings of massive
cortical and hippocampal atrophy due to progressive neur-
on loss have been reported in independently generated
cPS1xPS2KO mice [26]. The loss of presenilin function in
brain thus results in many phenotypes that are seen in AD.
New mouse models knock in
A caveat of most mouse models engineered to express
FAD mutant PS1 is that the transgene is overexpressed. If
PS FAD mutations cause a loss-of-function, this might be
compensated for by the increased expression. To circum-
vent this, Xia et al. created knockin (KI) mice, introdu-
cing two different human PS1 FAD mutations (L435F and
C410Y) into the mouse presenilin 1 gene locus [27].
Both mouse lines show normal levels of PS1 mRNA, but
a drastic reduction of endoproteolysis: PS1 holoprotein in-
creases and N- and C-terminal fragments decrease in a
KI allele dosage-dependent manner. Analysing three γ-
secretase substrates – APP, N-Cadherin and Notch – the
authors report a strong increase in their CTFs in both ho-
mozygous mouse lines, equivalent to the increase in ho-
mozygous PS1 KO mice. NICD generation is reduced in a
dosage-dependent manner, being virtually abolished in ho-
mozygous KI lines. At the same time, the generation of
Aβ40 and Aβ42 species is absent in homozygous mice.
Thus, both presenilin FAD mutations display a clear loss-
of-function phenotype, resulting in severe developmental
deficits, including decreased proliferation of progenitors
in the ventricular zone and thinning of the cortical plate,
closely resembling the phenotype of homozygous PS1 KO
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mice. In heterozygous KI mice the de novo production
of Aβ40 and Aβ42 is reduced by approximately 50% in
3-month-old animals, again pointing to a complete loss-of-
function due to the FAD mutation. In addition, insoluble
brain fractions displayed an increased Aβ42/Aβ40 ratio, a
finding also seen in FAD patients [28]. The catalytic core
of γ-secretase probably consists of a presenilin dimer [29],
although this is debated [30]. In heterozygous animals the
dimer can be a mix of wild type and FAD mutant presenil-
in. FAD mutations alter the conformation of presenilin,
thereby affecting how APP is presented to the active site
[31]. Homozygous FAD mutant mice have only mutated
presenilin in the dimer, inhibiting γ-secretase activity. In
heterozygous animals, the mutant presenilin obviously in-
fluences the conformation of the active wild-type version,
leading to APP cleavage at different positions that result in
increased Aβ42/Aβ40 ratios.
Crossing the KI mice with mice overexpressing mutant hu-
man APP allowed analysis of plaque deposition. As with
endogenous mouse Aβ, the insoluble fraction showed a
greater decrease of Aβ40, leading to an increased Aβ42/
Aβ40 ratio. Despite the decrease in total Aβ levels, the
plaque area in cortex at 9 months of age was 5-fold greater.
This is in line with data from the mouse models described
earlier. Expression of only Aβ without the rest of APP re-
vealed that the determining factor for plaque deposition is
the Aβ42/Aβ40 ratio, not the absolute amount of Aβ [3].
Besides the presenilin 1 gene, the homologous presenilin
2 gene is also affected by FAD mutations, albeit at lower
frequency. PS2 expression is upregulated in the absence of
PS1 and might then compensate for behavioural and syn-
aptic deficits caused by PS1 deficiency [32]. Therefore,
Xia et al. crossed the L435F KI mice onto a PS2 KO back-
ground. Heterozygous KI mice on this background showed
diverse synaptic deficits. The impaired synaptic plasticity
resulted in memory impairment, although the effects were
rather subtle. Heterozygous KI mice on a PS2 KO back-
ground, with additional deletion of the second wild type
presenilin 1 allele, showed the most dramatic effects. An-
imals aged twelve months showed increased activation of
astroglia and microglia in cortex and hippocampus, a cel-
lular reaction that classically accompanies AD. Most stun-
ningly, 12- and 18-month-old animals had reduced cortical
volume and neuron numbers with an increase in apoptot-
ic cells. These results are striking in the sense that this is
the first mouse model encompassing human FAD muta-
tions that shows massive age-dependent neurodegeneration
in the cortex. Nevertheless, one has to bear in mind that the
genotype of human FAD cases is very different. These pa-
tients still have one wild-type copy of the presenilin 1 and
both presenilin 2 alleles, in contrast to the mice showing
neurodegeneration that express only the FAD mutant copy
of presenilin 1. Still, this kind of genetic exaggeration is
common in mouse models – such as the overexpression of
FAD-APP – and is used to accelerate processes that take
10–20 years in humans, in order to be able to detect effects
during the short lifespan of mice. The findings in the new
mouse models show that FAD mutations in PS1 lead to a
clear loss-of-function – the question is: which function is
lost?
Loss-of-what?
APP is known to play a role in various cellular processes,
with the full-length protein itself, as well as the different
fragments produced by the secretase cleavages, being in-
volved in distinct functions, including cell adhesion, cell
proliferation, cell migration, neurite outgrowth, synapto-
genesis, nuclear signalling and regulation of copper, calci-
um and mitochondrial homeostasis [33, 34]. The extracel-
lular domain is shed through cleavage by α- or β-secretase,
with α-cleavage generating a secreted extracellular domain
(sAPPα) that has neuroprotective functions and promotes
neural progenitor proliferation. But, because α-cleavage
precedes APP cleavage by γ-secretase, sAPPα levels are
not expected to be directly affected by PS FAD mutations,
although this was not analysed by Xia et al. In addition
to reducing Aβ levels, loss-of-presenilin-function also re-
duces AICD production. AICD has been shown to translo-
cate to the nucleus and regulate transcription [35, 36], with
approximately 30 target genes described to date [21, 37].
Deregulated expression of these target genes might contrib-
ute to the cellular processes that ultimately result in neuro-
degeneration [38]. Target genes encompass proteins regu-
lating lipid, mitochondrial and APP metabolism, cell cycle,
proliferation, apoptosis, tumour suppression, cytoskeleton
and synaptic functions – all of which are reported to be
altered in AD.
In addition to the effects on APP, loss-of-function of
presenilin will affect many other γ-secretase substrates,
as shown for Notch and N-Cadherin by Xia et al. Notch
has important roles in development, but also in adulthood.
Consequently, the recent clinical trials targeting AD by
means of γ-secretase inhibition showed severe Notch-re-
lated side effects [39, 40]. Altered processing of these ad-
ditional substrates might also impact the degenerative pro-
cesses and could be involved in the earlier onset of the
disease in presenilin mutant carriers. Nevertheless, there
are nearly 50 different FAD mutations in APP and in these
cases there is no described effect on the other substrates.
Furthermore, in sporadic AD the major hallmark is amyloid
plaques derived from processing of APP. In the following
section, I have therefore restricted my discussion to APP.
Speculating beyond the cascade
What if Aβ were not the sole or major cause of neurodegen-
eration in AD? Toxicity has been observed with high con-
centrations of synthetic Aβ preparations in vitro. But, using
naturally secreted Aβ oligomers or those isolated from AD
brain, the described effects are restricted to synapses, with
impairment of synaptic plasticity and memory [41, 42]. Aβ
generation is induced by neuronal activity and it is there-
fore conceivable that Aβ oligomers are physiologic regu-
lators of synaptic plasticity and memory, with synapse loss
being reversible after removal of excess Aβ [43–45].
The lowering of Aβ levels with concomitant changes in the
Aβ42/Aβ40 ratio induced by PS FAD mutations or the in-
creased Aβ production due to higher β-secretase expres-
sion in sporadic AD [46], will probably lead to alterations
of synaptic plasticity that could manifest in memory prob-
lems. Over decades, this altered plasticity – leading to a net
Review article: Medical intelligence Swiss Med Wkly. 2015;145:w14233
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 3 of 6
loss of synapses – could result in failure of neurotrophic
support that relies on functioning synapses [47], resulting
in neuronal death. Amyloid plaques might be generated to
sequester excess amounts of Aβ that would disrupt memory
and thus, rather subserve a protective function. Accord-
ingly, amyloid plaques would only tell us that something is
wrong with APP metabolism, leading potentially to the de-
velopment of AD.
At the same time that Aβ generation is altered in familial
and sporadic AD, FAD PS mutations reduce AICD produc-
tion. What about FAD mutations in APP? Most of them
also lead to increased Aβ42/Aβ40 ratios. Processing of
APP CTFs by γ-secretase occurs in consecutive cleavages
along different product lines [48]. Whereas PS FAD muta-
tions block the fourth enzymatic cleavage, leading to ac-
cumulation of Aβ42 and Aβ43, APP FAD mutations cause
a shift towards the product line producing Aβ42 [49]. In
this product line, the initial ε-cleavage releases a one amino
acid longer AICD species that starts with a leucine, instead
of the N-terminal valine exposed in the product line leading
to Aβ40. AICD is suggested to be degraded via the pro-
teasome by an N-end rule-mediated pathway [50]. In this
pathway, the N-terminal amino acid determines the stabil-
ity of the protein, with valine being a stabilising and leu-
cine a destabilising residue. Together, these data imply that
the product line leading to higher Aβ42/Aβ40 ratios is in-
herently coupled to the production of less stable AICD
species. Thus, both PS and APP FAD mutations lead to
reduced AICD levels. The Swedish APP FAD mutation
stands out in that it does not change the Aβ42/Aβ40 ratio,
but increases the total level of Aβ, because this mutation
renders APP a better β-secretase substrate. Similarly, the
increased β-secretase activity in sporadic AD enhances Aβ
production [46]. In both cases, higher Aβ levels are ac-
companied by higher levels of AICD nuclear signalling, as
this depends on the β-secretase-mediated cleavage pathway
[51]. In addition to enhanced β-secretase activity, there is
also evidence for γ-secretase dysfunction in sporadic AD
[52] that might again alter AICD production. The result-
ing deregulation of AICD target genes could further disrupt
synaptic function, adding to the effects of Aβ. Increases in
β-secretase activity or reduction of γ-secretase activity will
also lead to the accumulation of βCTFs that can disrupt
neuronal functions, for instance by inducing mitochondri-
al dysfunction, enhancing endocytosis or disrupting axonal
transport of growth factors [53–55].
But what is finally responsible for neurodegeneration in
human AD patients? Excess Aβ can be captured in amyloid
plaques, whereas the deregulation of AICD-mediated tran-
scription might be more deleterious for neuronal survival.
As stated in the introduction, we need “continuous mani-
fold research” into all possible causes of AD to find a cure
for this disease.
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Figure 1
Proteolytic processing of the amyloid precursor protein (APP).
APP is a single-pass transmembrane protein with a large extracellular domain and the short APP intracellular domain (AICD) facing the
cytoplasm. Sequential proteolytic cleavage by the secretases occurs via two opposing pathways, both initiated by the release of the extracellular
domain. Non-amyloidogenic cleavage by α-secretase destroys the Aβ peptide and releases secreted APPα (sAPPα). This APP fragment
contains a growth factor-like domain (GFLD) and a copper-binding domain (CBD) and displays neuroprotective and neuroproliferative
properties. In the amyloidogenic pathway, cleavage by β-secretase generates the Aβ N-terminus and sAPPβ, which lacks the properties of
sAPPα. After release of the extracellular domain, the remaining APP transmembrane C-terminal fragments (CTFs) can enter the γ-secretase
complex to undergo regulated intramembrane proteolysis (RIP), which consists of consecutive cleavages denoted by three arrows. This initially
releases AICD from the membrane, which in the case of the amyloidogenic pathway can signal to the nucleus. In the same pathway, further
cleavages by γ-secretase shape the Aβ C-terminus that is critical for determining aggregation propensity. Aβ aggregates into different oligomeric
species that can induce synapse loss and neurofibrillary tangle (NFT) formation. Finally, Aβ deposits in large extracellular structures known as
amyloid plaques – besides NFTs, a hallmark of Alzheimer’s disease (AD).
Review article: Medical intelligence Swiss Med Wkly. 2015;145:w14233
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 6 of 6
